Author
Listed:
- Adrián Varela-Vázquez
(Universidade da Coruña (UDC), A Coruña, Spain)
The Institute of Cancer Research)
- Amanda Guitián-Caamaño
(Universidade da Coruña (UDC), A Coruña, Spain)
University College Dublin)
- Paula Carpintero-Fernández
(Universidade da Coruña (UDC), A Coruña, Spain))
- Alexander Carneiro-Figueira
(Universidade da Coruña (UDC), A Coruña, Spain))
- Vanesa Álvarez
(University of Dundee)
- Marta Varela-Eirín
(Universidade da Coruña (UDC), A Coruña, Spain))
- Teresa Calleja-Chuclá
(Universidade da Coruña (UDC))
- Susana B. Bravo-López
(Universidade de Santiago de Compostela (USC))
- Anxo Vidal
(Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS))
- Juan Sendón-Lago
(Universidade de Santiago de Compostela)
- Marina Rodriguez-Candela Mateos
(Universidade da Coruña (UDC))
- José R. Caeiro
(Universidade de Santiago de Compostela (USC))
- Victoria Sanz-Moreno
(The Institute of Cancer Research)
- Trond Aasen
(Autonomous University of Barcelona, CIBERONC)
- Miguel G. Blanco
(Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria (IDIS))
- Guadalupe Sabio
(Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria (IDIS))
- María Quindós
(Universidade da Coruña (UDC))
- Carmen Rivas
(Universidade de Santiago de Compostela
Consejo Superior de Investigaciones Científicas (CSIC))
- David Santamaría
(Centro de Investigación del Cáncer, CSIC. University of Salamanca)
- Carlos Fernandez-Lozano
(Universidade da Coruna)
- Eduardo Fonseca
(Universidade da Coruña (UDC), A Coruña, Spain)
Universidade da Coruña (UDC))
- Pablo Huertas
(Universidad de Sevilla-Consejo Superior de Investigaciones Científicas-Universidad Pablo de Olavide)
- Berta Sánchez-Laorden
(Consejo Superior de Investigaciones Científicas and Universidad Miguel Hernández)
- Constance Alabert
(University of Dundee)
- María D. Mayán
(Universidade da Coruña (UDC), A Coruña, Spain))
Abstract
BRAF and MEK inhibitors (BRAF/MEKi) have radically changed the treatment landscape of advanced BRAF mutation-positive tumours. However, limited efficacy and emergence of drug resistance are major barriers for successful treatments. Here, by using relevant preclinical models, we find that Connexin43 (Cx43), a protein that plays a role in cell-to-cell communication, enhances the effectiveness of BRAF/MEKi by recruiting DNA repair complexes to lamin-associated domains and promoting persistent DNA damage and cellular senescence. The nuclear compartmentalization promoted by Cx43 contributes to genome instability and synthetic lethality caused by excessive DNA damage, which could provide a therapeutic approach for these tumours to overcome drug resistance. Based on these findings, we designed a drug combination using small extracellular vesicles (sEVs) to deliver the full-Cx43 in combination with the BRAF/MEKi. This study reveals Cx43 as a regulator of DNA repair and BRAF/MEKi response, highlighting the therapeutic potential that this approach could eventually have in the clinic to overcome the limitations of current therapies and improve treatment outcomes for patients with advanced BRAF mutant tumours.
Suggested Citation
Adrián Varela-Vázquez & Amanda Guitián-Caamaño & Paula Carpintero-Fernández & Alexander Carneiro-Figueira & Vanesa Álvarez & Marta Varela-Eirín & Teresa Calleja-Chuclá & Susana B. Bravo-López & Anxo V, 2025.
"Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity,"
Nature Communications, Nature, vol. 16(1), pages 1-20, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60971-3
DOI: 10.1038/s41467-025-60971-3
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60971-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.